9. Jha MK, Sarode AY, Bodhale N, Mukherjee D, Pandey SP, Srivastava N, Rub A, Silvestre R, Sarkar A, Saha B. Development and characterization of an avirulent
Leishmania major strain. J Immunol 2020;204:2734-2753
https://doi.org/10.4049/jimmunol.1901362
11. Santana W, de Oliveira SS, Ramos MH, Santos ALS, Dolabella SS, Souto EB, Severino P, Jain S. Exploring innovative leishmaniasis treatment: drug targets from pre-clinical to clinical findings. Chem Biodivers 2021;18:e2100336
https://doi.org/10.1002/cbdv.202100336
13. de Morais RC, de Melo MG, de Goes TC, e Silva RP, de Morais RF, de Oliveira Guerra JA, de Brito ME, Brandão-Filho SP, de Paiva Cavalcanti M. Clinical-therapeutic follow-up of patients with American cutaneous leishmaniasis caused by different
Leishmania spp. in Brazil. Exp Parasitol 2022;240:108338
https://doi.org/10.1016/j.exppara.2022.108338
15. Alves F, Bilbe G, Blesson S, Goyal V, Monnerat S, Mowbray C, Muthoni Ouattara G, Pécoul B, Rijal S, Rode J, Solomos A. Recent development of visceral leishmaniasis treatments: successes, pitfalls, and perspectives. Clin Microbiol Rev 2018;31:e00048-18
https://doi.org/10.1128/CMR.00048-18
16. Zhang WW, Karmakar S, Gannavaram S, Dey R, Lypaczewski P, Ismail N, Siddiqui A, Simonyan V, Oliveira F, Coutinho-Abreu IV, DeSouza-Vieira T, Meneses C, Oristian J, Serafim TD, Musa A, Nakamura R, Saljoughian N, Volpedo G, Satoskar M, Satoskar S, Dagur PK, McCoy JP, Kamhawi S, Valenzuela JG, Hamano S, Satoskar AR, Matlashewski G, Nakhasi HL. A second generation leishmanization vaccine with a markerless attenuated
Leishmania major strain using CRISPR gene editing. Nat Commun 2020;11:3461
https://doi.org/10.1038/s41467-020-17154-z
17. Miramin-Mohammadi A, Javadi A, Eskandari SE, Nateghi-Rostami M, Khamesipour A. Immune responses in cutaneous leishmaniasis:
In vitro Thelper1/Thelper2 cytokine profiles using live versus killed
Leishmania major. J Arthropod Borne Dis 2021;15:126-135
https://doi.org/10.18502/jad.v15i1.6491
18. Carregaro V, Costa DL, Brodskyn C, Barral AM, Barral-Netto M, Cunha FQ, Silva JS. Dual effect of
Lutzomyia longipalpis saliva on
Leishmania braziliensis infection is mediated by distinct saliva-induced cellular recruitment into BALB/c mice ear. BMC Microbiol 2013;13:102
https://doi.org/10.1186/1471-2180-13-102
19. Helou DG, Mauras A, Fasquelle F, Lanza JS, Loiseau PM, Betbeder D, Cojean S. Intranasal vaccine from whole
Leishmania donovani antigens provides protection and induces specific immune response against visceral leishmaniasis. PLoS Negl Trop Dis 2021;15:e0009627
https://doi.org/10.1371/journal.pntd.0009627
20. Karmakar S, Ismail N, Oliveira F, Oristian J, Zhang WW, Kaviraj S, Singh KP, Mondal A, Das S, Pandey K, Bhattacharya P, Volpedo G, Gannavaram S, Satoskar M, Satoskar S, Sastry RM, Oljuskin T, Sepahpour T, Meneses C, Hamano S, Das P, Matlashewski G, Singh S, Kamhawi S, Dey R, Valenzuela JG, Satoskar A, Nakhasi HL. Preclinical validation of a live attenuated dermotropic
Leishmania vaccine against vector transmitted fatal visceral leishmaniasis. Commun Biol 2021;4:929
https://doi.org/10.1038/s42003-021-02446-x
22. Nylén S, Maasho K, Söderstrom K, Ilg T, Akuffo H. Live
Leishmania promastigotes can directly activate primary human natural killer cells to produce interferon-gamma. Clin Exp Immunol 2003;131:457-467
https://doi.org/10.1046/j.1365-2249.2003.02096.x
23. Kopelyanskiy D, Desponds C, Prevel F, Rossi M, Migliorini R, Snäkä T, Eren RO, Claudinot S, Lye LF, Pasparakis M, Beverley SM, Fasel N.
Leishmania guyanensis suppressed inducible nitric oxide synthase provoked by its viral endosymbiont. Front Cell Infect Microbiol 2022;12:944819
https://doi.org/10.3389/fcimb.2022.944819
24. Cecílio P, Cordeiro-da-Silva A, Oliveira F. Sand flies: Basic information on the vectors of leishmaniasis and their interactions with
Leishmania parasites. Commun Biol 2022;5:305
https://doi.org/10.1038/s42003-022-03240-z
26. Ikeogu NM, Akaluka GN, Edechi CA, Salako ES, Onyilagha C, Barazandeh AF, Uzonna JE.
Leishmania immunity: advancing immunotherapy and vaccine development. Microorganisms 2020;8:1201
https://doi.org/10.3390/microorganisms8081201
27. Natarajan G, Oghumu S, Varikuti S, Thomas A, Satoskar A. Mechanisms of immunopathology of leishmaniasis. In Satoskar AR, Durvasula R eds, Pathogenesis of Leishmaniasis. Springer. New York, USA. 2014, pp 1-13.
30. Hosseini Farash BR, Mohebali M, Kazemi B, Fata A, Hajjaran H, Akhoundi B, Raoofian R, Mastroeni P, Moghaddas E, Khaledi A, Salehi Sangani G. Validation of a mixture of rK26 and rK39 antigens from Iranian strain of
Leishmania infantum to detect anti-
Leishmania antibodies in human and reservoir hosts. Sci Rep 2022;12:10426
https://doi.org/10.1038/s41598-022-14490-6
31. Gomes DC, Souza BL, Schwedersky RP, Covre LP, de Matos Guedes HL, Lopes UG, Ré MI, Rossi-Bergmann B. Intranasal immunization with chitosan microparticles enhances LACK-DNA vaccine protection and induces specific long-lasting immunity against visceral leishmaniasis. Microbes Infect 2022;24:104884
https://doi.org/10.1016/j.micinf.2021.104884
32. Sumova P, Sanjoba C, Willen L, Polanska N, Matsumoto Y, Noiri E, Paul SK, Ozbel Y, Volf P. PpSP32-like protein as a marker of human exposure to
Phlebotomus argentipes in
Leishmania donovani foci in Bangladesh. Int J Parasitol 2021;51:1059-1068
https://doi.org/10.1016/j.ijpara.2021.05.006
34. Bhaumik SK, Singh MK, Karmakar S, De T. UDP-Gal: N-acetylglucosamine beta 1–4 galactosyltransferase expressing live attenuated parasites as vaccine for visceral leishmaniasis. Glycoconj J 2009;26:663-673
https://doi.org/10.1007/s10719-008-9212-y
37. Ostolin TL, Gusmão MR, Mathias FA, de Oliveira Cardoso JM, Roatt BM, de Oliveira Aguiar-Soares RD, Ruiz JC, de Melo Resende D, de Brito RC, Reis AB. A chimeric vaccine combined with adjuvant system induces immunogenicity and protection against visceral leishmaniasis in BALB/c mice. Vaccine 2021;39:2755-2763
https://doi.org/10.1016/j.vaccine.2021.04.004
38. Athanasiou E, Agallou M, Tastsoglou S, Kammona O, Hatzigeorgiou A, Kiparissides C, Karagouni E. A poly (lactic-co-glycolic) acid nanovaccine based on chimeric peptides from different
Leishmania infantum proteins induces dendritic cells maturation and promotes peptide-specific IFNγ-producing CD8+ T cells essential for the protection against experimental visceral leishmaniasis. Front Immunol 2017;8:684
https://doi.org/10.3389/fimmu.2017.00684
41. Oliveira F, Rowton E, Aslan H, Gomes R, Castrovinci PA, Alvarenga PH, Abdeladhim M, Teixeira C, Meneses C, Kleeman LT, Guimarães-Costa AB, Rowland TE, Gilmore D, Doumbia S, Reed SG, Lawyer PG, Andersen JF, Kamhawi S, Valenzuela JG. A sand fly salivary protein vaccine shows efficacy against vector-transmitted cutaneous leishmaniasis in nonhuman primates. Sci Transl Med 2015;7:290ra90
https://doi.org/10.1126/scitranslmed.aaa3043
42. Zahedifard F, Gholami E, Taheri T, Taslimi Y, Doustdari F, Seyed N, Torkashvand F, Meneses C, Papadopoulou B, Kamhawi S, Valenzuela JG, Rafati S. Enhanced protective efficacy of nonpathogenic recombinant
Leishmania tarentolae expressing cysteine proteinases combined with a sand fly salivary antigen. PLoS Negl Trop Dis 2014;8:e2751
https://doi.org/10.1371/journal.pntd.0009123
43. Davarpanah E, Seyed N, Bahrami F, Rafati S, Safaralizadeh R, Taheri T.
Lactococcus lactis expressing sand fly PpSP15 salivary protein confers long-term protection against
Leishmania major in BALB/c mice. PLoS Negl Trop Dis 2020;14:e0007939
https://doi.org/10.1371/journal.pntd.0007939
44. Mitchell GF, Handman E, Spithill TW. Vaccination against cutaneous leishmaniasis in mice using nonpathogenic cloned promastigotes of
Leishmania major and importance of route of injection. Aust J Exp Biol Med Sci 1984;62:145-153
https://doi.org/10.1038/icb.1984.14
45. Gorczynski RM. Immunization of susceptible BALB/c mice against
Leishmania braziliensis,: II. Use of temperature-sensitive avirulent clones of parasite for vaccination purposes. Cellular Immunol 1985;94:11-20
https://doi.org/10.1016/0008-8749(85)90081-4
46. Rivier D, Shah R, Bovay P, Mauel J. Vaccine development against cutaneous leishmaniasis. Subcutaneous administration of radioattenuated parasites protects CBA mice against virulent
Leishmania major challenge. Parasite Immunol 1993;15:75-84
https://doi.org/10.1111/j.1365-3024.1993.tb00587.x
47. Kimsey PB, Theodos CM, Mitchen TK, Turco SJ, Titus RG. An avirulent lipophosphoglycan-deficient
Leishmania major clone induces CD4+ T cells which protect susceptible BALB/c mice against infection with virulent
L. major. Infect Immun 1993;61:5205-5213
https://doi.org/10.1128/iai.61.12.5205-5213.1993
48. Daneshvar H, Coombs GH, Hagan P, Phillips RS.
Leishmania mexicana and
Leishmania major: attenuation of wild-type parasites and vaccination with the attenuated lines. J Infect Dis 2003;187:1662-1668
https://doi.org/10.1086/374783
49. Convit J, Ulrich M, Polegre MA, Avila A, Rodríguez N, Mazzedo MI, Blanco B. Therapy of Venezuelan patients with severe mucocutaneous or early lesions of diffuse cutaneous leishmaniasis with a vaccine containing pasteurized
Leishmania promastigotes and bacillus Calmette-Guerin: preliminary report. Mem Inst Oswaldo Cruz 2004;99:57-62
https://doi.org/10.1590/S0074-02762004000100010
50. Araújo MS, de Andrade RA, Vianna LR, Mayrink W, Reis AB, Sathler-Avelar R, Teixeira-Carvalho A, Andrade MC, Mello MN, Martins-Filho OA. Despite Leishvaccine and Leishmune trigger distinct immune profiles, their ability to activate phagocytes and CD8+ T-cells support their high-quality immunogenic potential against canine visceral leishmaniasis. Vaccine 2008;26:2211-2224
https://doi.org/10.1016/j.vaccine.2008.02.044
52. Convit J, Ulrich M, Zerpa O, Borges R, Aranzazu N, Valera M, Villarroel H, Zapata Z, Tomedes I. Immunotherapy of american cutaneous leishmaniasis in Venezuela during the period 1990–99. Trans R Soc Trop Med Hyg 2003;97:469-472
https://doi.org/10.1016/S0035-9203(03)90093-9
54. Velez R, Gállego M. Commercially approved vaccines for canine leishmaniosis: a review of available data on their safety and efficacy. Trop Med Int Health 2020;25:540-557
https://doi.org/10.1111/tmi.13382
55. Borja-Cabrera GP, Santos FN, Bauer FS, Parra LE, Menz I, Morgado AA, Soares IS, Batista LMM, Palatnik-de-Sousa CB. Immunogenicity assay of the Leishmune® vaccine against canine visceral leishmaniasis in Brazil. Vaccine 2008;26:4991-4997
https://doi.org/10.1016/j.vaccine.2008.07.029
58. Parody N, Soto M, Requena JM, Alonso C. Adjuvant guided polarization of the immune humoral response against a protective multicomponent antigenic protein (Q) from
Leishmania infantum. A CpG+Q mix protects Balb/c mice from infection. Parasite Immunol 2004;26:283-293
https://doi.org/10.1111/j.0141-9838.2004.00711.x
59. Ahmed SB, Bahloul C, Robbana C, Askri S, Dellagi K. A comparative evaluation of different DNA vaccine candidates against experimental murine leishmaniasis due to
L. major. Vaccine 2004;22:1631-1639
https://doi.org/10.1016/j.vaccine.2003.10.046
60. Olobo JO, Anjili CO, Gicheru MM, Mbati PA, Kariuki TM, Githure JI, Koech DK, McMaster WR. Vaccination of vervet monkeys against cutaneous leishmaniosis using recombinant
Leishmania ‘major surface glycoprotein’ (gp63). Vet Parasitol 1995;60:199-212
https://doi.org/10.1016/0304-4017(95)00788-6
61. Gurunathan S, Sacks DL, Brown DR, Reiner SL, Charest H, Glaichenhaus N, Seder RA. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with
Leishmania major. J Exp Med 1997;186:1137-1147
https://doi.org/10.1084/jem.186.7.1137
62. Yang DM, Fairweather N, Button LL, McMaster WR, Kahl LP, Liew FY. Oral Salmonella typhimurium (AroA-) vaccine expressing a major Leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis. J Immunol 1990;145:2281-2285.
63. McMahon-Pratt D, Rodriguez D, Rodriguez JR, Zhang Y, Manson K, Bergman C, Rivas L, Rodriguez JF, Lohman KL, Ruddle NH. Recombinant vaccinia viruses expressing GP46/M-2 protect against
Leishmania infection. Infect Immun 1993;61:3351-3359
https://doi.org/10.1128/iai.61.8.3351-3359.1993
65. Handman E, Symons FM, Baldwin TM, Curtis JM, Scheerlinck JP. Protective vaccination with promastigote surface antigen 2 from
Leishmania major is mediated by a TH1 type of immune response. Infect Immun 1995;63:4261-4267
https://doi.org/10.1128/iai.63.11.4261-4267.1995
66. Santos WR, Aguiar IA, de Souza EP, de Lima VM, Palatnik M, Palatnik-de-Sousa CB. Immunotherapy against murine experimental visceral leishmaniasis with the FML-vaccine. Vaccine 2003;21:4668-4676
https://doi.org/10.1016/S0264-410X(03)00527-9
68. Coler RN, Duthie MS, Hofmeyer KA, Guderian J, Jayashankar L, Vergara J, Rolf T, Misquith A, Laurance JD, Raman VS, Bailor HR, Cauwelaert ND, Reed SJ, Vallur A, Favila M, Orr MT, Ashman J, Ghosh P, Mondal D, Reed SG. From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE. Clin Transl Immunology 2015;4:e35
https://doi.org/10.1038/cti.2015.6
70. Chakravarty J, Kumar S, Trivedi S, Rai VK, Singh A, Ashman JA, Laughlin EM, Coler RN, Kahn SJ, Beckmann AM, Cowgill KD, Reed SG, Sundar S, Piazza FM. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine 2011;29:3531-3537
https://doi.org/10.1016/j.vaccine.2011.02.096
73. Papadopoulou B, Roy G, Breton M, Kündig C, Dumas C, Fillion I, Singh AK, Olivier M, Ouellette M. Reduced infectivity of a
Leishmania donovani biopterin transporter genetic mutant and its use as an attenuated strain for vaccination. Infect Immun 2002;70:62-68
https://doi.org/10.1128/IAI.70.1.62-68.2002
74. Silvestre R, Cordeiro-Da-Silva A, Santarém N, Vergnes B, Sereno D, Ouaissi A. SIR2-deficient
Leishmania infantum induces a defined IFN-gamma/IL-10 pattern that correlates with protection. J Immunol 2007;179:3161-3170
https://doi.org/10.4049/jimmunol.179.5.3161
75. Carrión J, Folgueira C, Soto M, Fresno M, Requena JM.
Leishmania infantum HSP70-II null mutant as candidate vaccine against leishmaniasis: a preliminary evaluation. Parasit Vectors 2011;4:150
https://doi.org/10.1186/1756-3305-4-150
76. Ghosh A, Labrecque S, Matlashewski G. Protection against
Leishmania donovani infection by DNA vaccination: increased DNA vaccination efficiency through inhibiting the cellular p53 response. Vaccine 2001;19:3169-3178
https://doi.org/10.1016/S0264-410X(01)00023-8
77. Dey R, Dagur PK, Selvapandiyan A, McCoy JP, Salotra P, Duncan R, Nakhasi HL. Live attenuated
Leishmania donovani p27 gene knockout parasites are nonpathogenic and elicit long-term protective immunity in BALB/c mice. J Immunol 2013;190:2138-2149
https://doi.org/10.4049/jimmunol.1202801
78. Walker PS, Scharton-Kersten T, Rowton ED, Hengge U, Bouloc A, Udey MC, Vogel JC. Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis. Hum Gene Ther 1998;9:1899-1907
https://doi.org/10.1089/hum.1998.9.13-1899
79. Mutiso JM, Macharia JC, Kiio MN, Ichagichu JM, Rikoi H, Gicheru MM. Development of
Leishmania vaccines: predicting the future from past and present experience. J Biomed Res 2013;27:85-102
https://doi.org/10.7555/JBR.27.20120064
80. Aunguldee T, Gerdprasert O, Tangteerawatana P, Jariyapongskul A, Leelayoova S, Wongsatayanon BT. Immunogenicity and potential protection of DNA vaccine of
Leishmania martiniquensis against
Leishmania infection in mice. J Infect Dev Ctries 2021;15:1328-1338
https://doi.org/10.3855/jidc.14472
81. Rafati S, Zahedifard F, Azari MK, Taslimi Y, Taheri T.
Leishmania infantum: prime boost vaccination with C-terminal extension of cysteine proteinase type I displays both type 1 and 2 immune signatures in BALB/c mice. Exp Parasitol 2008;118:393-401
https://doi.org/10.1016/j.exppara.2007.10.004
82. Prasanna P, Kumar P, Kumar S, Rajana VK, Kant V, Prasad SR, Mohan U, Ravichandiran V, Mandal D. Current status of nanoscale drug delivery and the future of nano-vaccine development for leishmaniasis–a review. Biomed Pharmacother 2021;141:111920
https://doi.org/10.1016/j.biopha.2021.111920
84. Taheri T, Rafati S. Leishmaniasis: recombinant DNA vaccination and different approaches for vaccine development. Clin Invest 2013;3:1023-1044
https://doi.org/10.4155/CLI.13.99
85. Volpedo G, Huston RH, Holcomb EA, Pacheco-Fernandez T, Gannavaram S, Bhattacharya P, Nakhasi HL, Satoskar AR. From infection to vaccination: reviewing the global burden, history of vaccine development, and recurring challenges in global leishmaniasis protection. Expert Rev Vaccines 2021;20:1431-1446
https://doi.org/10.1080/14760584.2021.1969231
86. Cecílio P, Pérez-Cabezas B, Fernández L, Moreno J, Carrillo E, Requena JM, Fichera E, Reed SG, Coler RN, Kamhawi S, Oliveira F, Valenzuela JG, Gradoni L, Glueck R, Gupta G, Cordeiro-da-Silva A. Pre-clinical antigenicity studies of an innovative multivalent vaccine for human visceral leishmaniasis. PLoS Negl Trop Dis 2017;11:e0005951
https://doi.org/10.1371/journal.pntd.0005951
87. Osman M, Mistry A, Keding A, Gabe R, Cook E, Forrester S, Wiggins R, Di Marco S, Colloca S, Siani L, Cortese R, Smith DF, Aebischer T, Kaye PM, Lacey CJ. A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: first-in-human trial of ChAd63-KH. PLoS Negl Trop Dis 2017;11:e0005527
https://doi.org/10.1371/journal.pntd.0005527
89. Margaroni M, Agallou M, Athanasiou E, Kammona O, Kiparissides C, Gaitanaki C, Karagouni E. Vaccination with poly(D,L-lactide-co-glycolide) nanoparticles loaded with soluble
Leishmania antigens and modified with a TNFα-mimicking peptide or monophosphoryl lipid A confers protection against experimental visceral leishmaniasis. Int J Nanomedicine 2017;12:6169-6184
https://doi.org/10.2147/IJN.S141069
90. Taslimi Y, Zahedifard F, Taheri T, Doroud D, Dizaji SL, Saljoughian N, Rafati S. Comparison of protective potency of DNA and live vaccines expressing A2-CPA-CPB
−CTE antigens against visceral leishmaniasis in Syrian hamster as preliminary study. Iran J Parasitol 2020;15:383-392
https://doi.org/10.18502/ijpa.v15i3.4203
91. Lage DP, Ribeiro PA, Dias DS, Mendonça DV, Ramos FF, Carvalho LM, de Oliveira D, Steiner BT, Martins VT, Perin L, Machado AS, Santos TTO, Tavares GSV, Oliveira-da-Silva JA, Oliveira JS, Roatt BM, Machado-de-Ávila RA, Teixeira AL, Humbert MV, Coelho EAF, Christodoulides M. A candidate vaccine for human visceral leishmaniasis based on a specific T cell epitope-containing chimeric protein protects mice Against
Leishmania infantum infection. NPJ Vaccines 2020;5:75
https://doi.org/10.1038/s41541-020-00224-0
92. Alves-Silva MV, Nico D, de Luca PM, Palatnik de-Sousa CB. The F1F3 recombinant chimera of
Leishmania donovani-Nucleoside Hydrolase (NH36) and its epitopes induce cross-protection against
Leishmania (V.) braziliensis infection in mice. Front Immunol 2019;10:724
https://doi.org/10.3389/fimmu.2019.00724
93. Klatt S, Simpson L, Maslov DA, Konthur Z.
Leishmania tarentolae: taxonomic classification and its application as a promising biotechnological expression host. PLoS Negl Trop Dis 2019;13:e0007424
https://doi.org/10.1371/journal.pntd.0007424
94. Mendoza-Roldan JA, Latrofa MS, Iatta R, Manoj RSR, Panarese R, Annoscia G, Pombi M, Zatelli A, Beugnet F, Otranto D. Detection of
Leishmania tarentolae in lizards, sand flies and dogs in southern Italy, where
Leishmania infantum is endemic: hindrances and opportunities. Parasit Vectors 2021;14:461
https://doi.org/10.1186/s13071-021-04973-2
96. Panasiuk M, Zimmer K, Czarnota A, Grzyb K, Narajczyk M, Peszyńska-Sularz G, Żołędowska S, Nidzworski D, Hovhannisyan L, Gromadzka B. Immunization with
Leishmania tarentolae-derived norovirus virus-like particles elicits high humoral response and stimulates the production of neutralizing antibodies. Microbial Cell Factories 2021;20:186
https://doi.org/10.1186/s12934-021-01677-1
97. Moura AP, Santos LC, Brito CR, Valencia E, Junqueira C, Filho AA, Sant’Anna MR, Gontijo NF, Bartholomeu DC, Fujiwara RT, Gazzinelli RT, McKay CS, Sanhueza CA, Finn MG, Marques AF. Virus-like particle display of the α-Gal carbohydrate for vaccination against
Leishmania infection. ACS central science 2017;3:1026-1031
https://doi.org/10.1021/acscentsci.7b00311
100. Duthie MS, Van Hoeven N, MacMillen Z, Picone A, Mohamath R, Erasmus J, Hsu FC, Stinchcomb DT, Reed SG. Heterologous immunization with defined RNA and subunit vaccines enhances T Cell responses that protect against
Leishmania donovani. Front Immunol 2018;9:2420
https://doi.org/10.3389/fimmu.2018.02420